Trials / Recruiting
RecruitingNCT07531693
Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer
Patient Relevant Outcomes Improvement Program in High Risk HR-positive Breast Cancer
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Institut fuer Frauengesundheit · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this observational study is to evaluate how persistently patients with high-risk early breast cancer take abemaciclib 6 months after therapy start. To this end, researchers will perform a retrospective analysis of therapy data.
Conditions
Timeline
- Start date
- 2026-02-19
- Primary completion
- 2026-09-01
- Completion
- 2027-03-01
- First posted
- 2026-04-15
- Last updated
- 2026-04-15
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT07531693. Inclusion in this directory is not an endorsement.